More than $492 Billion in New U.S. Investment in 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
This year, the life sciences sector has delivered.
We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $492 billion being invested to drive new R&D, expand manufacturing and create jobs nationwide. Our continually updated database is accessible below through a state map of announcements that mention specific cities or states and also a tracker of every public commitment since January 2025.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, powering high-skill positions for scientists and engineers, construction and production support roles, and millions of jobs for the communities surrounding the facilities. This builds upon more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
The tracker reflects the sector’s commitment to preserving American leadership in the life sciences, as China continues a coordinated campaign to overtake it.
1,488%
increase in announced U.S. facility investments versus 2024
Tens of Thousands
of new construction jobs across America
Faster delivery
of breakthrough medicines to U.S. patients
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
U.S. Biopharma Investment Watch
Legend:
Announcement date
Company
Investment amount
Investment location(s)
Dec 9, 2025
Eli Lilly
$6 billion
Huntsville-AL
A new, next-generation active pharmaceutical ingredient (API) facility that will support the production of small molecule synthetic and peptide medicines, including an oral GLP-1. The project will bring “450 high-value jobs” to the area, including engineers, scientists, operations personnel and lab technicians, and 3,000 construction jobs.
Part of a larger, previously announced $27 billion company investment.
Nov 21, 2025
AstraZeneca
$2 billion
Frederick-MD, Gaithersburg-MD
Expansion of the company’s flagship biologics manufacturing facility in Frederick and the construction of a new state-of-the-art facility in Gaithersburg for the development of innovative molecules to be used in clinical trials.
The investment will support 2,600 jobs across the two sites, including the retention of local jobs, construction activity, and the creation of 300 highly skilled jobs.
Part of a larger, previously announced $50 billion company investment.
Nov 19, 2025
Novartis
Unspecified
Durham-NC, Morrisville-NC
A new site in Durham featuring two facilities dedicated to manufacturing biologics and sterile packaging. Also an expansion of an existing Durham facility with the added capability to support sterile filling of biologics into syringes and vials.
A new site in Morrisville with one facility for the production of solid dosage tablets and capsules, including packaging.
Part of a larger, previously announced $23 billion company investment.
Oct 29, 2025
Eli Lilly
$1.2 billion
Carolina-PR
Expansion and modernization of the Lilly del Caribe manufacturing site to support the company's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology. The project will generate an estimated 1,000 construction jobs and 100 additional high-tech manufacturing positions.
Part of a larger, previously announced $27 billion company investment.
Oct 20, 2025
Merck
$70 billion
Unspecified location
Investment in U.S. capital projects, research and development to drive long-term growth and fortify America’s position as a global leader in drug innovation.
Amount includes previously announced projects in Rahway, NJ, Wilmington, DE, and Elkton, VA, which represent an estimated $7.5 billion commitment. The company also disclosed $3 billion in planned biologics and small molecule manufacturing sites and capabilities in the U.S., projected to create 800 additional jobs.
Oct 20, 2025
Merck
$3 billion
Elkton–VA
Broke ground on a project to enhance an existing site with a 400,000-square-foot Center of Excellence for pharmaceutical manufacturing. The facility will support small molecule manufacturing and testing and will potentially create more than 500 full-time roles as well as 8,000 construction jobs.
Part of a $70 billion U.S. investment plan.
Oct 10, 2025
Ypsomed
$248 million
Holly Springs-NC
A 15,000-square-meter factory that will be the Switzerland-based company’s first manufacturing facility in the United States. The facility will supply products solely for the U.S. market and is expected to create around 100 new jobs, with the goal of expanding the workforce to about 200 in the coming years as demand increases.
Oct 9, 2025
AstraZeneca
$4.5 billion
Albemarle-VA
A new manufacturing facility that is scheduled to increase output of various medicines, including cancer treatments, once operational within the next five to six years. Will create 3,600 direct and indirect jobs, including 3,000 tied to the project's construction phase.
Part of a larger, previously announced $50 billion investment.
No entries found matching your criteria. Please modify your filters.
Methodology
All investments data comes from publicly available resources. Investments may span across multiple states and, therefore, are reflected on each state page. Investment locations will be updated once specified.
-
Jobs data source: WWFH “in the states” page
-
Labor hours data source: PILMA jobs report page